Prostatype Genomics AB (publ) (STO:PROGEN)

Prostatype Genomics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	0.59	1.92	3.73	0.68	2.51
Other Revenue	0	-	-	-	-
Revenue	0.6	1.92	3.73	0.68	2.51
Revenue Growth (YoY)	-68.87%	-48.55%	445.83%	-72.78%	-16.56%
Cost of Revenue	20.8	22.36	19.83	13.49	8.49
Gross Profit	-20.2	-20.44	-16.1	-12.81	-5.98
Selling, General & Admin	15.23	15.71	18.1	10.39	7.98
Research & Development	1.46	2.21	3.23	3.51	1.49
Other Operating Expenses	-0.14	0.52	-0.06	0.08	0.01
Operating Expenses	18.74	20.42	23.14	15.88	9.57
Operating Income	-38.94	-40.85	-39.25	-28.69	-15.55
Interest Expense	-1.62	-1.68	-1.54	-0.4	-0.08
Interest & Investment Income	0.09	0.04	0	-	-
Currency Exchange Gain (Loss)	-4.04	1.44	-0.65	-	-
Other Non Operating Income (Expenses)	0	0	-	-0	-
Pretax Income	-44.5	-41.05	-41.44	-29.09	-15.63
Net Income	-44.5	-41.05	-41.44	-29.09	-15.63
Net Income to Common	-44.5	-41.05	-41.44	-29.09	-15.63
Shares Outstanding (Basic)	-	1	0	0	0
Shares Outstanding (Diluted)	-	1	0	0	0
Shares Change (YoY)	-	1645.51%	343.99%	28.75%	-
EPS (Basic)	-	-29.10	-512.68	-1597.92	-1105.51
EPS (Diluted)	-	-29.10	-512.68	-1597.92	-1105.51
Free Cash Flow	-24.06	-44.99	-29.21	-27.69	-16.08
Free Cash Flow Per Share	-	-31.89	-361.46	-1521.34	-1137.23
Gross Margin	-	-	-	-	-238.34%
Operating Margin	-6522.28%	-2130.03%	-1052.76%	-4200.44%	-619.54%
Profit Margin	-7454.44%	-2140.30%	-1111.45%	-4258.71%	-622.79%
Free Cash Flow Margin	-4029.98%	-2345.88%	-783.61%	-4054.61%	-640.66%
EBITDA	-38.82	-40.73	-39.23	-28.64	-15.46
D&A For EBITDA	0.12	0.12	0.02	0.05	0.09
EBIT	-38.94	-40.85	-39.25	-28.69	-15.55
Revenue as Reported	0.6	1.98	3.79	0.68	2.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.